Extended Data Fig. 5: JAK1 and STAT1 genomic alterations is correlated with poor outcome of patients with mCRPC.
a, Number of PCa cases with genomic alterations (amplification or mutation) in the loci of key JAK–STAT signaling genes in the mCRPC tumors of the SU2C cohort, compared to the number in the primary tumors of the TCGA PanCancer cohort. TCGA PanCancer = 489 tumors, SU2C = 444 tumors. b, Number of PCa cases with genomic alterations (amplification or mutation) in the loci of key JAK–STAT signaling genes in the mCRPC tumors of the SU2C cohort, compared to the frequency in the primary tumors of the TCGA Cell 2015 cohort. TCGA Cell 2015 = 333 tumors, SU2C = 444 tumors. For panel (a-b), p-values were calculated using two-tails Fisher’s exact test and annotated in figures. c, Expression (RSEM) of JAK–STAT signaling genes in patients with regional lymph nodes metastasis (N1, n = 80 tumors) compared to patients without regional lymph nodes metastasis (N0, n = 345 tumors). d, Expression (RSEM) of JAK–STAT signaling genes in the high-grade tumors (Gleason score ≥ 8, n = 206 tumors) compared to the low-grade tumors (Gleason score ≤ 7, n = 292 tumors). For panel (c-d), mean ± s.d. is represented and p-values were calculated using two-sided Mann–Whitney test and annotated in figures.
